Form 4: Inhibikase Therapeutics Director Dennis Berman Granted Over 108,000 Stock Options

Inhibikase Therapeutics, Inc. Director Dennis N. Berman was granted 108,176 stock options with an exercise price of $1.95, vesting by June 30, 2026, or the next annual meeting.

Summary

• Director Dennis N. Berman of Inhibikase Therapeutics, Inc. (IKT) was granted 108,176 stock options.
• The options have an exercise price of $1.95 per share.
• The transaction date for the grant was June 30, 2025.
• The options expire on June 30, 2032.
• The options will vest on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders, contingent on continued service.
• Following this transaction, Dennis N. Berman beneficially owns 108,176 derivative securities.
• A Limited Power of Attorney was executed on July 2, 2025, appointing David McIntyre and Mark Iwicki as attorneys-in-fact for SEC filings on behalf of Dennis Berman.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive sign, indicating continued commitment and alignment of interests. It's a routine compensation event, not indicative of major operational changes, hence a neutral-to-positive score.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $1.95 provides a clear benchmark for future stock performance relative to the grant.

Risks

• The reporting person retains full responsibility for compliance with Section 16 of the Securities Exchange Act of 1934 and Rule 144, despite the use of an attorney-in-fact for filing.
• Neither the company nor the attorney-in-fact assumes liability for the reporting person's compliance failures or disgorgement of profits under Section 16(b).

Future Outlook

The granted stock options are subject to future vesting conditions, specifically on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders, contingent on the director's continued service.

Management Comments

• The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
• This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information.
• Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigneds responsibility to comply with the requirements of Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act.
• This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 16 of the Exchange Act.

Industry Context

This is a standard insider transaction disclosure for a director in a publicly traded company, common across all industries, including the biotechnology/pharmaceutical sector where Inhibikase Therapeutics operates. Such grants are a typical component of executive and director compensation packages designed to align interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, similar to compensation structures seen at companies like Biogen Inc. or Gilead Sciences, Inc., where equity incentives are used to attract and retain talent and align long-term interests.
• The vesting schedule, tied to continued service and an annual meeting, is a standard mechanism for retaining directors and ensuring their commitment, consistent with corporate governance best practices in the sector.
• The exercise price of $1.95 is set at the market price on the grant date, which is typical for incentive stock options, ensuring that the options gain value only if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with those of shareholders, as the options gain value only if the stock price increases, potentially incentivizing decisions that benefit long-term shareholder value.

Next Steps

• The stock options will vest on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders.
• Dennis N. Berman will continue to be subject to Section 16 reporting requirements for his holdings and transactions in company securities.

Key Dates

Recommendation

Keywords

Inhibikase Therapeutics, IKT, Dennis Berman, Stock Options, SEC Form 4, Insider Trading, Director Compensation, Equity Grant, Derivative Securities, Corporate Governance